Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Items 101–200 of 1,000
Waizenegger, I. C., Baum, A., Steurer, S., Stadtmüller, H., Bader, G., Schaaf, O., Garin-Chesa, P., Schlattl, A., Schweifer, N., Haslinger, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0617 · Cited by 97
Aboukameel, A., Muqbil, I., Senapedis, W. T., Baloglu, E., Landesman, Y., Shacham, S., Kauffman, M. G., Philip, P. A., Mohammad, R. M., & Azmi, A. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0205 · Cited by 102
Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology
Guo, S.-W. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz047 · Cited by 96
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V. M., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., THOMAS, G. V., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0134-5 · Cited by 104
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 111
BET Inhibition Overcomes Receptor Tyrosine Kinase–Mediated Cetuximab Resistance in HNSCC
Leonard, B. C., Brand, T. M., O’Keefe, R. A., Lee, E. D., Zeng, Y., Kemmer, J. D., Li, H., Grandis, J. R., & Bhola, N. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0459 · Cited by 103
Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Yin, C., Zhu, B., Zhang, T., Liu, T., Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.002 · Cited by 94
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling
Dhawan, N. S., Scopton, A. P., & Dar, A. C. (2016) · Nature · doi:10.1038/nature19327 · Cited by 93
Strub, T., Ghiraldini, F. G., Carcamo, S., Li, M., Wroblewska, A., Singh, R., Goldberg, M. S., Hasson, D., Wang, Z., Gallagher, S. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05966-z · Cited by 93
Newman, S., Fan, L., Pribnow, A. K., Silkov, A., Rice, S. V., Lee, S., Shao, Y., Shaner, B., Mulder, H. L., Nakitandwe, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0373-y · Cited by 101
Pan, X., Pei, J., Wang, A., Wen, S., Feng, L., Bu, F., Zhu, Y., Zhang, L., Wang, G., & Ouyang, L. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.022 · Cited by 97
Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
Wu, P., Becker, A., & Park, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155436 · Cited by 96
TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination
Zhu, G., Herlyn, M., & Yang, X. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00732-8 · Cited by 90
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Sulahian, R., Kwon, J. J., Walsh, K. H., Pailler, E., Bosse, T. L., Thaker, M., Almanza, D., Dempster, J. M., Pan, J., Piccioni, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.090 · Cited by 90
The ERK cascade inhibitors: Towards overcoming resistance
Maik-Rachline, G., & Seger, R. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.12.001 · Cited by 95
Multitarget Drugs: an Epigenetic Epiphany
Ganesan, A. (2016) · ChemMedChem · doi:10.1002/cmdc.201500394 · Cited by 93
miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
Xiao, S., Yang, M., Yang, H., Chang, R., Fang, F., & Yang, L. (2018) · Oncogenesis · doi:10.1038/s41389-018-0097-8 · Cited by 88
The Role of Regulated Programmed Cell Death in Osteoarthritis: From Pathogenesis to Therapy
Liu, S., Pan, Y., Li, T., Zou, M., Liu, W., Li, Q., Wan, H., Peng, J., & Hao, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065364 · Cited by 105
Inhibition of miR-328–3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer
Srivastava, A. K., Banerjee, A. T., Cui, T., Han, C., Cai, S., Liu, L., Wu, D., Cui, R., Li, Z., Zhang, X., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3668 · Cited by 90
Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum
Motta, M., Pannone, L., Pantaleoni, F., Bocchinfuso, G., Radio, F. C., Cecchetti, S., Ciolfi, A., Rocco, M. D., Elting, M. W., Brilstra, E. H., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.06.018 · Cited by 103
Sun, C., Zhu, Y., Li, X., Wang, X., Tang, L., Su, Z., Li, C., Zheng, G., & Feng, B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00092 · Cited by 91
Lu, S., Banerjee, A., Jang, H., Zhang, J., Gaponenko, V., & Nussinov, R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664755 · Cited by 85
Bad phosphorylation as a target of inhibition in oncology
Bui, N.-L.-C., Pandey, V., Zhu, T., Ma, L., Basappa, & Lobie, P. E. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.017 · Cited by 86
Posttranslational Modifications of RAS Proteins
Ahearn, I., Zhou, M., & Philips, M. R. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031484 · Cited by 86
CIC protein instability contributes to tumorigenesis in glioblastoma
Bunda, S., Heir, P., Metcalf, J. L., Li, A. S. C., Agnihotri, S., Pusch, S., Mamatjan, Y., Li, M., Burrell, K. E., Mansouri, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08087-9 · Cited by 97
Inhibitors of BRAF dimers using an allosteric site
Cotto-Rios, X. M., Agianian, B., Gitego, N., Zacharioudakis, E., Giricz, O., Wu, Y., Zou, Y., Verma, A., Poulikakos, P. I., & Gavathiotis, E. (2020) · Nature Communications · doi:10.1038/s41467-020-18123-2 · Cited by 84
Self-citationMAPK kinase signalling dynamics regulate cell fate decisions and drug resistance
Rauch, N., Rukhlenko, O. S., Kölch, W., & Kholodenko, B. Ν. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.019 · Cited by 96
Pierozan, P., Cattani, D., & Karlsson, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02848-6 · Cited by 89
Ghaddar, N., Wang, S., Woodvine, B., Krishnamoorthy, J., van Hoef, V., Darini, C., Kazimierczak, U., Ah-son, N., Popper, H. H., Johnson, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24661-0 · Cited by 88
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 82
Szlachta, K. A., Kuscu, C., Tufan, T., Adair, S. J., Shang, S., Michaels, A. D., Mullen, M. G., Fischer, N. L., Yang, J., Liu, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06676-2 · Cited by 93
Anderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80
“The activity of single agent therapies targeting individual RAS effector pathways is limited; however, combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems (Al-Lazikani et al., 2012; Samatar and Poulikakos, 2014).”
BackgroundJones, G. G., del Río, I. B., Sari, S., Sekerim, A., Young, L. C., Hartig, N., Areso Zubiaur, I., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 80
Rovida, E., & Stecca, B. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.003 · Cited by 79
Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies
Yang, L., Zheng, L., Chng, W. J., & Ding, J. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.005 · Cited by 84
Yang, L., Shen, C., Estrada‐Bernal, A., Robb, R. N., Chatterjee, M., Sebastian, N., Webb, A., Mo, X. M., Chen, W., Krishnan, S., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab871 · Cited by 82
The Triple Crown: NO, CO, and H2S in cancer cell biology
Oza, P. P., & Kashfi, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108502 · Cited by 84
Mitochondrial Metabolism: Yin and Yang for Tumor Progression
Valcárcel-Jiménez, L., Gaude, E., Torrano, V., Frezza, C., & Carracedo, A. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.06.004 · Cited by 80
Molecular Mechanisms of Anticancer Activities of Puerarin
Ahmad, B., Khan, S., Liu, Y., Xue, M., Nabi, G., Kumar, S., Alshwmi, M., & Qarluq, A. W. (2020) · Cancer Management and Research · doi:10.2147/cmar.s233567 · Cited by 89
Liu, X., Xing, Y., Li, M., Zhang, Z., Wang, J., Ri, M., Jin, C. H., Xu, G., Piao, L. X., Jin, H., et al. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.113989 · Cited by 82
Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia
Poudel, G., Tolland, M., Hughes, T. P., & Pagani, I. S. (2022) · Cancers · doi:10.3390/cancers14143300 · Cited by 85
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells
Neault, M., Mallette, F. A., & Richard, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.068 · Cited by 84
Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer
Guo, J., Liu, C., Wang, W., Liu, Y., He, H., Chen, C., Xiang, R., & Luo, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200716 · Cited by 76
Selective Targeting of RSK Isoforms in Cancer
Casalvieri, K. A., Matheson, C. J., Backos, D. S., & Reigan, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.03.004 · Cited by 78
ERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis
Ali, E. S., Sahu, U., Villa, E., O’Hara, B. P., Gao, P., Beaudet, C., Wood, A. W., Asara, J. M., & Ben‐Sahra, I. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.001 · Cited by 81
Affinity and dose of TCR engagement yield proportional enhancer and gene activity in CD4+ T cells
Allison, K. A., Sajti, E., Collier, J. G., Gosselin, D., Troutman, T. D., Stone, E. L., Hedrick, S. M., & Glass, C. K. (2016) · eLife · doi:10.7554/elife.10134 · Cited by 74
Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo
Huang, T., Xiao, Y., Lin, Y., Li, L., Wang, M., Cheng, T., Ma, H., He, K., Wang, Y., Han, B., et al. (2017) · Scientific Reports · doi:10.1038/srep38524 · Cited by 79
Genomic Alterations in Langerhans Cell Histiocytosis
Rollins, B. J. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.06.004 · Cited by 73
Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.066 · Cited by 72
“However, conventional continuous administration of MEKis achieves an inadequate inhibition of ERK activity, which induces feedback regulation of other proliferation and survival pathways and re-activates MEK-ERK signaling, leading to drug resistance (Samatar and Poulikakos, 2014; Sun et al., 2014).”
BackgroundProtein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway
García-Gómez, R., Bustelo, X. R., & Crespo, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.07.002 · Cited by 72
Zhong, X., Zheng, L., Shen, J., Zhang, D., Xiong, M., Zhang, Y., He, X., Tanyi, J. L., Yang, F., Montone, K. T., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-16 · Cited by 73
Zhan, H., Bhattacharya, S., Cai, H., Iglesias, P. A., Huang, C., & Devreotes, P. N. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.08.001 · Cited by 76
Xue, T., Liu, X., Zhang, M., Qiukai, E., Liu, S., Zou, M., Li, Y., Ma, Z., Han, Y., Thompson, P. R., et al. (2021) · Advanced Science · doi:10.1002/advs.202002831 · Cited by 76
Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities
Fu, D., Hu, Z., Xu, X., Dai, X., & Liu, Z. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101510 · Cited by 91
Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies
Yousef, M., & Tsiani, E. (2017) · Cancers · doi:10.3390/cancers9050045 · Cited by 77
Kong, P., Dong, J., Li, W., Li, Z., Gao, R., Liu, X., Wang, J., Su, Q., Wen, B., Ouyang, W., et al. (2023) · Advanced Science · doi:10.1002/advs.202301244 · Cited by 86
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Dolivo, D. M., Larson, S. A., & Dominko, T. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.08.013 · Cited by 69
Adamopoulos, C., Ahmed, T. A., Tucker, M. R., Ung, P. M. U., Xiao, M., Karoulia, Z., Amabile, A., Wu, X., Aaronson, S. A., Ang, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1351 · Cited by 67
Self-citationBeyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response
Zhang, H., Fu, L., Leiliang, X., Qu, C., Wu, W., Wen, R., Huang, N., He, Q., Cheng, Q., Liu, G., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12597 · Cited by 78
Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
Luo, L.-X., Li, Y., Liu, Z.-Q., Fan, X.-X., Duan, F.-G., Li, R.-Z., Yao, X.-J., Leung, E. L.-H., & Liu, L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00199 · Cited by 68
ERK5 is activated by oncogenic BRAF and promotes melanoma growth
Tusa, I., Gagliardi, S., Tubita, A., Pandolfi, S., Urso, C., Borgognoni, L., Wang, J., Deng, X., Gray, N. S., Stecca, B. A., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0164-9 · Cited by 70
The emerging role for Cullin 4 family of E3 ligases in tumorigenesis
Cheng, J., Guo, J., North, B. J., Tao, K., Zhou, P., & Wei, W. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.007 · Cited by 74
Clinical Pharmacokinetics of Vemurafenib
Zhang, W., Heinzmann, D., & Grippo, J. F. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0523-7 · Cited by 84
Yan, X., Li, P., Zhan, Y., Qi, M., Liu, J., An, Z., Yang, W., Xiao, H., Wu, H., Qi, Y., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.031 · Cited by 65
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0431-3 · Cited by 67
“However, as each of these resistance mechanisms has converged on reactivation of the MAPK pathway and increased phosphorylated ERK levels, improved MAPK targeting through combination therapies or direct ERK targeting remains a treatment option for this type of resistance [62].”
BackgroundAssessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67
“Multiple inhibitors are being explored to target MEK/ERK and PI3K/AKT (13), two major signaling pathways downstream of KRAS.”
BackgroundMechanisms of resistance in head and neck cancer.
Picon, H., & Guddati, A. K. (2020) · PubMed · Cited by 93
Potočnjak, I., Šimić, L., Gobin, I., Vukelić, I., & Domitrović, R. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104852 · Cited by 69
Bronte, E., Bronte, G., Novo, G., Bronte, F., Bavetta, M. G., Re, G. L., Brancatelli, G., Bazan, V., Natoli, C., Novo, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5853 · Cited by 64
Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition
Diedrich, B., Rigbolt, K. T. G., Röring, M., Herr, R., Kaeser-Pebernard, S., Gretzmeier, C., Murphy, R. F., Brummer, T., & Dengjel, J. (2017) · The EMBO Journal · doi:10.15252/embj.201694732 · Cited by 67
Hong, A., Piva, M., Liu, S., Hugo, W., Lomeli, S. H., Zoete, V., Randolph, C. E., Yang, Z., Wang, Y., Lee, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0873 · Cited by 70
Jansen, R. W., van Amstel, P., Martens, R. M., Kooi, I. E., Wesseling, P., de Langen, A. J., Menke-Van der Houven van Oordt, C. W., Jansen, B. H. E., Moll, A. C., Dorsman, J. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24893 · Cited by 63
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Massimino, M., Stella, S., Tirrò, E., Romano, C., Pennisi, M. S., Puma, A., Manzella, L., Zanghì, A., Stagno, F., Raimondo, F. D., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0805-1 · Cited by 66
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer
Ludwik, K. A., Campbell, J. P., Li, M., Li, Y., Sandusky, Z. M., Pasic, L., Sowder, M. E., Brenin, D. R., Pietenpol, J. A., O'Doherty, G. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0106 · Cited by 68
Rahman, A. U., Pallichankandy, S., Thayyullathil, F., & Galadari, S. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.01.039 · Cited by 63
Hispidulin: A novel natural compound with therapeutic potential against human cancers
Ashaq, A., Maqbool, M. F., Maryam, A., Khan, M. N., Shakir, H. A., Irfan, M. I., Qazi, J. I., Li, Y., & Ma, T. (2020) · Phytotherapy Research · doi:10.1002/ptr.6862 · Cited by 65
An operational view of intercellular signaling pathways
Antebi, Y. E., Nandagopal, N., & Elowitz, M. B. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2016.12.003 · Cited by 61
MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance
Gao, X., Chen, G., Gao, C., Zhang, D. H., Kuan, S., Stabile, L. P., Liu, G., & Hu, J. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12055 · Cited by 67
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
Sadozai, H., Gruber, T., Hunger, R. E., & Schenk, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01617 · Cited by 67
Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
He, M., Lv, W., & Rao, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.685106 · Cited by 65
Recent progress on MAP kinase pathway inhibitors
Uehling, D., & Harris, P. A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.093 · Cited by 68
The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells
Fey, D., Matallanas, D., Rauch, J., Rukhlenko, O. S., & Kholodenko, B. N. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.011 · Cited by 61
Quercetin as an anticancer agent: Focus on esophageal cancer
Davoodvandi, A., Varkani, M. S., Clark, C. C. T., & Jafarnejad, S. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13374 · Cited by 65
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60
Zhao, Q., Peng, C. Y., Huang, H., Liu, S., Zhong, Y., Huang, W., He, G., & Han, B. (2018) · Chemical Communications · doi:10.1039/c8cc04732d · Cited by 62
Xia, Y., Jin, J., Sun, Y., Kong, X., Shen, Z., Yan, R., Huang, R., Liu, X., Xia, W., Ma, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113499 · Cited by 76
Multifunctional DDX3: dual roles in various cancer development and its related signaling pathways.
Zhao, L., Mao, Y., Zhou, J., Zhao, Y., Cao, Y., & Chen, X. '. (2016) · PubMed · Cited by 68
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
Maiti, A., Naqvi, K. Z., Kadia, T. M., Borthakur, G. M., Takahashi, K., Bose, P., Daver, N. G., Patel, A. P., Alvarado, Y., Ohanian, M. N., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.009 · Cited by 62
Relaxation oscillations and hierarchy of feedbacks in MAPK signaling
Kochańczyk, M., Kocieniewski, P., Kozłowska, E., Jaruszewicz-Błońska, J., Sparta, B., Pargett, M., Albeck, J. G., Hlavacek, W. S., & Lipniacki, T. (2017) · Scientific Reports · doi:10.1038/srep38244 · Cited by 59
“−∞ EGF r t s r t G r t t t ( , ) ( , ) ( , )d (5) t”
Recent advances in cancer drug discovery targeting RAS
Wilson, C., & Tolias, P. P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.002 · Cited by 66
Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis · doi:10.1038/s41389-019-0158-7 · Cited by 58
FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance
Bartel, C. A., Parameswaran, N., Cipriano, R., & Jackson, M. W. (2016) · Oncotarget · doi:10.18632/oncotarget.9544 · Cited by 64
Zhang, R., Wang, G., Zhang, P., Zhang, J., Huang, Y., Lu, Y., Da, W., Sun, Q., & Zhu, J. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13043 · Cited by 57
Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF
Gunderwala, A. Y., Nimbvikar, A., Cope, N. J., Li, Z., & Wang, Z. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00191 · Cited by 59
Gu, H., Yan, C., Wan, H., Wu, L., Liu, J., Zhu, Z., & Gao, D.-Z. (2021) · Human Cell · doi:10.1007/s13577-021-00599-9 · Cited by 60
Integrator orchestrates RAS/ERK1/2 signaling transcriptional programs
Yue, J., Lai, F., Beckedorff, F., Zhang, A., Pastori, C., & Shiekhattar, R. (2017) · Genes & Development · doi:10.1101/gad.301697.117 · Cited by 58
LIU, J., Li, Q., Liu, Z., Lin, L., ZHANG, X., Cao, M., & Jiang, J. (2016) · Oncology Reports · doi:10.3892/or.2016.4695 · Cited by 57
Chen, X., Yin, Y., Cheng, J., Huang, A., Hu, B., Zhang, X., Sun, Y., Wang, J., Wang, Y., Ji, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1087-7 · Cited by 61
MiR-326: Promising Biomarker for Cancer
Pan, Y., Wan, J., & Wang, C. (2019) · Cancer Management and Research · doi:10.2147/cmar.s223875 · Cited by 59
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.